CClinicalTrials.gg
CompletedNCT01357070Updated Jul 8, 2019

Effect of Broccoli Sprout on Blood Levels of Sulforaphane to Reduce Responsiveness of Immune System

An interventional study of Brocco-sprout homogenate and Alfalfa sprout homogenate in Healthy Volunteers, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Imperial College London · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators suggest that inducing anti-oxidant enzymes indirectly may be an effective means of providing vascular protection.

Sulforaphane, a naturally occurring compound found in green vegetables (including broccoli, brussel sprouts and cauliflower) is able to protect against cell inflammatory stress by inducing a number of anti-oxidant molecules. Targeted studies on the consumption of broccoli and related vegetables have been shown to be associated with reduced risk of coronary artery disease.

In the present study the investigators want to test whether the consumption of a "broccoli smoothie" containing sulforaphane can protect white blood cells from becoming activated in the presence of an experimental stress and how long this protective effect lasts for. To do this, the investigators will be analysing inflammatory changes in blood samples taken at different times during the study.

Read the detailed description

Atherosclerosis is the disease process that leads to hardening of the arteries which causes them to become narrowed. This occurs because fat is first deposited on the inside walls of the arteries, then becomes hardened by fibrous tissue and calcium deposition forming a semi-hardened accumulation of material known as plaque. As this plaque grows, it narrows the channel within the artery and causes a reduction in blood and oxygen supply to the affected organ - such as the heart and brain. The investigators now understand that this process is caused by inflammation and activation of the immune cells over a period of time. It has been proposed that targeting these immune cells and reducing the levels of immune activation can protect against cardiovascular diseases.

Previously it has been observed that consumption of fruit and vegetables rich in anti-oxidants can confer a protective effect against cardiovascular diseases. The use of anti-oxidants experimentally has shown protective benefits against activation.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • white blood cell
  • broccoli
  • P38 Map Kinase
03

In context

Lead sponsor

Imperial College London is the lead sponsor of 825 studies on the registry; 179 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18+ years
  • Able to commit for the two week duration of the trial

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Pregnancy
  • Vegetarian
  • History of allergy
  • Current smoker or smoking cessation within the last 3 months
  • Current use of inhaled, topical or systemic corticosteroids or within the last 2 weeks
  • Current use of non-steroidal anti-inflammatory use or within the last 1 week
  • Current use of nutritional or multivitamin supplements
  • Current participation in any other Randomised controlled trial
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Active comparator
    Brocco-sprout homogenate

    Dietary Supplement: Brocco-sprout homogenate

  • Sham comparator
    Alfalfa sprout homogenate

    Dietary Supplement: Alfalfa sprout homogenate

Interventions

  • Dietary supplementBrocco-sprout homogenate

    Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).

  • Dietary supplementAlfalfa sprout homogenate

    Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.

06

What researchers measure

Primary outcomes

  1. Resistance of leucocytes to inflammatory activation following an experimental stress

    Participants will consume a brocco-sprout homogenate. Blood will be sampled for intracellular markers of leukocyte stress after ex-vivo stimulus with Phorbol ester / Tumour Necrosis Factor alpha. The following parameters will be recorded. 1. Reactive oxygen species detection using aminophenylfluoresceine dye 2. p38 MAP kinase induction 3. NF-kB induction

    Time frame: 24 hours after consumption of the third homogenate

07

Study locations

1 site
  • Cardiovascular Medicine Research Unit, Hammersmith Hospital
    London, W12 0NN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01357070
Lead sponsor
Imperial College London
Responsible party
Sponsor
First posted
May 20, 2011
Start date
May 2011
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Jul 8, 2019

Study contacts

Paul C Evans, BSc MSc PhD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion